Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2015, to report on a corporate update provided by CEO Dr. Leonard S. Schleifer at the J.P. Morgan Healthcare Conference. The primary focus of this update, and thus the key takeaway for investors from this filing, concerns the preliminary U.S. net sales figures for EYLEA® (aflibercept) Injection for the full year 2014. While specific sales numbers are not detailed within the 8-K text itself, the filing indicates that this information was presented and is available in the accompanying presentation (Exhibit 99.1). Investors interested in Regeneron's top-line performance, particularly for its flagship product EYLEA, should refer to the furnished presentation for the actual sales data and any forward-looking statements or strategic insights shared by management during the conference.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2015.
- 2The filing provides a corporate update from CEO Dr. Leonard S. Schleifer at the J.P. Morgan Healthcare Conference.
- 3Key information pertains to preliminary U.S. net sales for EYLEA® (aflibercept) Injection for the full year 2014.
- 4The presentation containing these sales figures is furnished as Exhibit 99.1.
- 5This 8-K serves to inform the market about recent company performance, specifically related to EYLEA sales.
- 6The information is not considered 'filed' for Section 18 purposes, but is incorporated by reference in the 8-K.